TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06619034: iMMagine-3: Phase 3 Study of Anitocabtagene Autoleucel (anito-cel) ddBCMA CAR-T vs Standard Regimens in Relapsed/Refractory Multiple Myeloma

Sponsor: Arcellx, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06619034 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06619034 Rescue Dossier →